vs
CytomX Therapeutics, Inc.（CTMX）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
REDWOOD TRUST INC的季度营收约是CytomX Therapeutics, Inc.的1.4倍（$25.9M vs $18.7M），REDWOOD TRUST INC净利率更高（77.2% vs -0.8%，领先78.1%），REDWOOD TRUST INC同比增速更快（-6.1% vs -25.7%），过去两年CytomX Therapeutics, Inc.的营收复合增速更高（-15.9% vs -41.0%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
CTMX vs RWT — 直观对比
营收规模更大
RWT
是对方的1.4倍
$18.7M
营收增速更快
RWT
高出19.6%
-25.7%
净利率更高
RWT
高出78.1%
-0.8%
两年增速更快
CTMX
近两年复合增速
-41.0%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $25.9M |
| 净利润 | $-154.0K | $20.0M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | — |
| 净利率 | -0.8% | 77.2% |
| 营收同比 | -25.7% | -6.1% |
| 净利润同比 | 97.6% | 402.6% |
| 每股收益（稀释后） | — | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXRWT
| Q4 25 | — | $25.9M | ||
| Q3 25 | — | $15.0M | ||
| Q2 25 | $18.7M | $13.8M | ||
| Q1 25 | $50.9M | $27.9M | ||
| Q4 24 | $38.1M | $27.6M | ||
| Q3 24 | $33.4M | $25.5M | ||
| Q2 24 | $25.1M | $67.4M | ||
| Q1 24 | $41.5M | $74.5M |
净利润CTMXRWT
| Q4 25 | — | $20.0M | ||
| Q3 25 | — | $-7.7M | ||
| Q2 25 | $-154.0K | $-98.5M | ||
| Q1 25 | $23.5M | $16.1M | ||
| Q4 24 | $18.9M | $-6.6M | ||
| Q3 24 | $5.7M | $14.8M | ||
| Q2 24 | $-6.5M | $15.5M | ||
| Q1 24 | $13.8M | $30.3M |
营业利润率CTMXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | -9.0% | ||
| Q2 25 | -6.9% | -679.0% | ||
| Q1 25 | 44.4% | 80.2% | ||
| Q4 24 | 46.4% | -1.3% | ||
| Q3 24 | 12.3% | 86.1% | ||
| Q2 24 | -33.7% | 30.3% | ||
| Q1 24 | 28.1% | 41.3% |
净利率CTMXRWT
| Q4 25 | — | 77.2% | ||
| Q3 25 | — | -51.4% | ||
| Q2 25 | -0.8% | -712.0% | ||
| Q1 25 | 46.2% | 57.8% | ||
| Q4 24 | 49.6% | -24.0% | ||
| Q3 24 | 17.2% | 58.1% | ||
| Q2 24 | -26.0% | 23.0% | ||
| Q1 24 | 33.3% | 40.6% |
每股收益（稀释后）CTMXRWT
| Q4 25 | — | $0.11 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $-0.76 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $-0.08 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $0.10 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $255.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $982.6M |
| 总资产 | $175.1M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXRWT
| Q4 25 | — | $255.7M | ||
| Q3 25 | — | $226.3M | ||
| Q2 25 | $49.0M | $302.0M | ||
| Q1 25 | $47.6M | $259.9M | ||
| Q4 24 | $38.1M | $245.2M | ||
| Q3 24 | $40.6M | $253.7M | ||
| Q2 24 | $43.2M | $275.6M | ||
| Q1 24 | $36.2M | $275.4M |
总债务CTMXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.7B |
股东权益CTMXRWT
| Q4 25 | — | $982.6M | ||
| Q3 25 | — | $999.0M | ||
| Q2 25 | $119.9M | $1.1B | ||
| Q1 25 | $25.0M | $1.2B | ||
| Q4 24 | $-456.0K | $1.2B | ||
| Q3 24 | $-23.5M | $1.2B | ||
| Q2 24 | $-31.2M | $1.2B | ||
| Q1 24 | $-31.7M | $1.2B |
总资产CTMXRWT
| Q4 25 | — | $23.7B | ||
| Q3 25 | — | $22.6B | ||
| Q2 25 | $175.1M | $21.3B | ||
| Q1 25 | $98.5M | $19.9B | ||
| Q4 24 | $120.5M | $18.3B | ||
| Q3 24 | $139.0M | $18.4B | ||
| Q2 24 | $159.2M | $16.5B | ||
| Q1 24 | $184.7M | $15.1B |
负债/权益比CTMXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | — |
| 自由现金流率自由现金流/营收 | -84.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | -504.15× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | — |
8季度趋势，按日历期对齐
经营现金流CTMXRWT
| Q4 25 | — | $-10.1B | ||
| Q3 25 | — | $-2.7B | ||
| Q2 25 | $-15.8M | $-2.1B | ||
| Q1 25 | $-21.0M | $-2.0B | ||
| Q4 24 | $-19.9M | $-5.9B | ||
| Q3 24 | $-20.7M | $-2.1B | ||
| Q2 24 | $-19.5M | $-2.0B | ||
| Q1 24 | $-26.0M | $-954.2M |
自由现金流CTMXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
自由现金流率CTMXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
资本支出强度CTMXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
现金转化率CTMXRWT
| Q4 25 | — | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | -120.92× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | -1.89× | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RWT
暂无分部数据
